Ovid Therapeutics Inc. Common Stock (OVID) Stock Price

OVIDStock

$2.80+124.00%52W

Market Cap$546.83M

P/E—

PEG Ratio—

Div yield—

Beta0.27

OVID Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)73.50%

Price vs S&P 500 (4W)18.63%

VGM Score63.01

Book Value / Share (Quarterly)$1.19

P/TBV (Annual)0.89x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)69.09%

Cash Flow / Share (Quarterly)$-0.25

Price vs S&P 500 (YTD)58.96%

Net Profit Margin (TTM)-240.13%

EPS (TTM)$-0.24

10-Day Avg Trading Volume1.63M

EPS Excl Extra (TTM)$-0.24

Revenue Growth (5Y)-10.46%

EPS (Annual)$-0.24

ROI (Annual)-13.33%

Net Profit Margin (5Y Avg)-4365.33%

Cash / Share (Quarterly)$0.93

Revenue Growth QoQ (YoY)844.74%

ROA (Last FY)-11.54%

Revenue Growth TTM (YoY)1199.64%

EBITD / Share (TTM)$-0.53

ROE (5Y Avg)-16.86%

Operating Margin (TTM)-585.20%

Cash Flow / Share (Annual)$-0.29

P/B Ratio2.62x

P/B Ratio (Quarterly)1.69x

Net Income / Employee (Annual)$-757,100

EV / Revenue (TTM)58.58x

ROA (TTM)-18.67%

EV / EBITDA (TTM)3.41x

EPS Incl Extra (Annual)$-0.24

Current Ratio (Annual)8.97x

Quick Ratio (Quarterly)9.88x

3-Month Avg Trading Volume2.13M

52-Week Price Return124.00%

Revenue / Employee (TTM)$309,700

Tangible BV / Share (Quarterly)$1.19

P/S Ratio (Annual)71.55x

Asset Turnover (Annual)0.05x

52-Week High$3.10

Operating Margin (5Y Avg)-6058.75%

EPS Excl Extra (Annual)$-0.24

CapEx CAGR (5Y)-4.25%

Tangible BV CAGR (5Y)24.72%

26-Week Price Return85.43%

Quick Ratio (Annual)8.40x

13-Week Price Return6.06%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.17x

Enterprise Value$424.80M

Revenue / Share Growth (5Y)-14.50%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)8.63%

Revenue / Employee (Annual)$315,300

Pretax Margin (Annual)-240.13%

Cash / Share (Annual)$0.53

3-Month Return Std Dev59.73%

Net Income / Employee (TTM)$-1,050,700

ROE (Last FY)-13.33%

EPS Basic Excl Extra (Annual)$-0.24

Receivables Turnover (TTM)4168.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.24

ROI (TTM)-22.51%

P/S Ratio (TTM)71.55x

Pretax Margin (5Y Avg)-4365.20%

Revenue / Share (Annual)$0.10

Tangible BV / Share (Annual)$1.00

Price vs S&P 500 (52W)105.44%

Year-to-Date Return71.78%

5-Day Price Return-0.71%

EPS Normalized (Annual)$-0.24

ROA (5Y Avg)-9.66%

Net Profit Margin (Annual)-240.13%

Month-to-Date Return26.13%

Cash Flow / Share (TTM)$-0.68

EBITD / Share (Annual)$-0.57

Operating Margin (Annual)-585.20%

ROI (5Y Avg)-16.86%

EPS Basic Excl Extra (TTM)$-0.24

P/TBV (Quarterly)1.69x

P/B Ratio (Annual)0.89x

Pretax Margin (TTM)-240.13%

Book Value / Share (Annual)$1.00

Price vs S&P 500 (13W)4.11%

Beta0.27x

P/FCF (Annual)4.38x

Revenue / Share (TTM)$0.05

ROE (TTM)-22.51%

52-Week Low$1.12

vGradeC

gGradeB

mGradeB

vgmGradeB

OVID Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.10	-$0.08	+23.29%(+$0.02)
Q1 2026	May 12, 2026	-$0.11	-$0.12	-13.21%(-$0.01)
Q4 2025	Mar 18, 2026	-$0.10	$0.06	+161.22%(+$0.16)
Q3 2025	Nov 12, 2025	-$0.15	-$0.17	-14.86%(-$0.02)
Q2 2025	Aug 13, 2025	-$0.15	-$0.06	+59.32%(+$0.09)

OVID Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.35

4.38

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
OVIDOvid Therapeutics Inc. Common Stock	C	B	B	$2.80
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Ovid Therapeutics Inc. Common Stock

Ovid Therapeutics is a biopharmaceutical company developing novel treatments for rare epilepsies and seizure-related neurological disorders. The company's pipeline features multiple programs with potential first-in-class and best-in-class mechanisms of action, targeting patient populations with limited treatment options.